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ABSTRACT
Metronomic chemotherapy has shown promising activity in numerous preclinical 
studies and also some phase II clinical studies involving various tumor types, and 
is currently undergoing phase III trial evaluation. Triple-negative breast cancer 
(TNBC) is an aggressive histological subtype with limited treatment options and very 
poor prognosis following progression after standard chemotherapeutic regimens. 
Herein, we evaluated the potential therapeutic impact and molecular mechanisms of 
topotecan administered in a continuous low-dose metronomic (LDM) manner, alone 
or in concurrent combination with pazopanib, an antiangiogenic tyrosine kinase 
inhibitor (TKI), in a triple-negative, primary and metastatic breast cancer orthotopic 
model; potential molecular mechanisms of efficacy were also studied, especially 
the impact of hypoxic conditions. The combination of metronomic topotecan and 
pazopanib significantly enhanced antitumor activity compared to monotherapy with 
either drug and prolonged survival, even in the advanced metastatic survival setting, 
with a marked decrease in tumor vascularity, proliferative index, and the induction 
of apoptosis. Significant changes in tumor angiogenesis, cancer cell proliferation, 
apoptosis, HIF1α levels, HIF-1 target genes and ABCG2 were found both in vitro 
and in tumor tissue. Notably, the pazopanib and metronomic topotecan combination 
treatment inhibited expression of HIF1α and ABCG2 genes in cells grown under hypoxic 
conditions, and this was associated with an increased intracellular concentration of 
the active form of topotecan. Our results suggest a potential novel therapeutic option 
for the treatment of metastatic triple-negative breast cancer patients.
INTRODUCTION
Metronomic chemotherapy refers to the close, 
regular administration of conventional chemotherapy 
drugs at low, minimally toxic doses, with no prolonged 
break periods [1]. Integration with an antiangiogenic 
agent such as TKIs (e.g. sunitinib and pazopanib) or 
anti-VEGFR-2 monoclonal antibodies (i.e. DC101) with 
metronomic chemotherapy can greatly enhance antitumor 
efficacy, with low toxicity [2]. Metronomic chemotherapy 
has shown encouraging results in a number of phase II 
clinical trials, including in metastatic breast cancer [3-6], 
and is currently undergoing phase III trial evaluation [7-9]. 
One completed randomized phase III trial, called CAIRO3, 
evaluating metronomic capecitabine plus bevacizumab as 
a long-term maintenance therapy in first line metastatic 
colorectal cancer patients, reported significantly improved 
progression free survival (PFS) rate, the primary endpoint 
of the study [10]. Topotecan, a topoisomerase I inhibitor, 
appears to be highly efficacious both in animal models 
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and in human patients when administered for prolonged 
periods using metronomic dosing [11-15]. Moreover, 
metronomic oral topotecan showed an enhanced antitumor 
activity as a result of combination with concurrent 
administration of pazopanib, in preclinical models of 
advanced human ovarian cancer [16, 17], aggressive 
pediatric solid tumors [18], pediatric sarcomas [19], and 
renal cell carcinoma [20]. Indeed, a phase I trial of this 
combination schedule has been conducted in persistent 
gynecologic tumors, without major toxic effects [21]. 
Pazopanib, approved in 2009 for the treatment of patients 
with advanced renal cell carcinoma (RCC) [22], is 
currently being evaluated alone or in combination with 
capecitabine in breast cancer patients [23, 24]. Several 
phase I trials were performed to assess the safety and 
tolerability of pazopanib in patients with advanced solid 
tumors [25-27], but the activity of pazopanib alone in 
metastatic breast cancer has been established only in a 
single arm open-label multicenter phase II trial, where 
pazopanib provided disease stability in advanced breast 
cancer and the authors suggested its use in breast cancer 
in combination with chemotherapeutic drugs and/or other 
targeted agents [28]. Few preclinical and clinical data are 
currently available concerning the impact of topotecan 
in metastatic breast cancer and its metronomic dosing 
and scheduling concept has not yet been explored in 
this indication either alone or in combination with TKIs 
[29]. Among breast cancer subtypes, “triple-negative” 
is particularly aggressive with limited treatment options 
available, and associated with a very poor prognosis [30]. 
The purpose of our study was to investigate metronomic 
topotecan alone or in combination with pazopanib in a 
model of a primary established triple-negative or advanced 
metastatic breast cancer elucidating possible molecular 
mechanisms accounting for efficacy of this treatment 
combination. 
RESULTS
In vitro studies
Pazopanib, sunitinib or topotecan inhibit 
endothelial and cancer cell proliferation in vitro
In vitro pazopanib, sunitinib and topotecan inhibited 
the cell proliferation of HUVEC, HMVEC-d and of 231/
LM2-4 in a time- and concentration-dependent manner 
(see Supplementary Table 1); the 72-h pazopanib, 
sunitinib and topotecan standard exposures inhibited the 
proliferation of 231/LM2-4 with an IC50 of 11±0.67 µM, 
8±0.73 µM and 24±2.07 nM, respectively, being different 
from those observed in the 144-h metronomic exposure 
(2.18±0.53 µM, 2.63±0.33 µM and 3.01±0.58 nM, 
respectively). Moreover, a greater antiproliferative effect 
of pazopanib, sunitinib or topotecan, in the metronomic 
144-h exposure, on HUVECs was found, as demonstrated 
by the IC50 values (1±0.22 µM, 3±0.95 nM and 1±0.13 
nM respectively). The cytotoxic activity on proliferating 
HMVEC-d was similar to that observed for HUVECs (IC50 
values are reported in Supplementary Table 1). 
Protracted low-dose treatment with topotecan 
and TKIs modulates expression of HIF1α in 
endothelial and cancer cells 
After exposure to pazopanib, sunitinib or topotecan 
and various concurrent combinations of these drugs 
at concentration corresponding to the experimental 
IC50 of cell proliferation, HIF1α gene expression and 
protein levels were evaluated in cells treated in hypoxic 
conditions. Low dose topotecan significantly inhibited 
HIF1α gene expression in 231/LM2-4 in hypoxic 
conditions (54±1.41 % vs. 100% of control expression. P 
< 0.001; Figure 1A). As shown in Supplementary Figure 
1, a single standard 72h-exposure of topotecan did not 
decrease hypoxia-induced HIF1α gene expression as 
much as protracted low-dose topotecan, corroborating 
that the effects of topotecan on HIF1α were even more 
marked when cells were treated with daily administration 
of low metronomic doses of drug (72h standard exposure 
69±0.64% and 144h metronomic daily exposure 
54±1.41% vs. 100% of control expression. P < 0.001; 
Supplementary Figure 1). In hypoxic conditions both TKIs 
and low dose topotecan inhibit HIF1α gene expression, 
but the combination significantly reduces this gene 
expression more than the metronomic topotecan and TKIs 
alone as follows: pazopanib daily exposure 68±0.14% 
vs. topotecan + pazopanib daily exposure 16±1.37%, 
and sunitinib daily exposure 80±0.32% vs. topotecan + 
sunitinib daily exposure 14±1.87% if compared to 100% 
control expression (Figure 1A). Also the HIF1α protein 
level (Figure 1B) confirmed this marked inhibition when 
compared to LDM topotecan or TKIs alone. 
Pazopanib or sunitinib enhances the effect of 
protracted low-dose treatment with topotecan in 
an hypoxic environment
The combination of topotecan with pazopanib 
enhances the anti-proliferative effect on 231/LM2-4 cells 
of the individual drugs used alone, as shown in Figure 1C. 
To investigate in more detail the basis of this enhanced 
effect, we measured the intracellular concentration of 
topotecan lactone in treated cells. Higher topotecan lactone 
concentrations were found in 231/LM2-4, MDA-MB-231 
and endothelial cells exposed to the drugs in combination 
with either pazopanib or sunitinib, when compared 
with treatment using topotecan alone. Our results show 
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Figure 1: A. HIF1α gene expression in 231/LM2-4 cells exposed to metronomic topotecan (TPT), pazopanib (PZ), sunitinib (SU) and 
combinations thereof or with vehicle alone, for 144h in hypoxic conditions. Columns and bars, mean values ±S.E., respectively. *P < 0.001 
vs. vehicle-treated controls. B. HIF1α protein expression in 231/LM2-4 cells exposed to metronomic topotecan (LDM TPT), pazopanib, 
sunitinib or combinations thereof or with vehicle alone, for 144h in hypoxic conditions. C. Sigmoid concentration-effect curve of 231/
LM2-4 cells exposed to metronomic TPT, PZ or combinations thereof [1:10], or with vehicle alone for 144h. D. Accumulation of topotecan 
in 231/LM2-4 cell line after exposure to 1 µM topotecan alone and in combination with pazopanib or sunitinib. Columns and bars indicate 
mean values±S.D., respectively. Small S.D. bars are not visible in the graph. E. ABCG2 gene expression in 231/LM2-4 cells exposed to 
metronomic topotecan, pazopanib, sunitinib or combinations thereof, or with vehicle alone, for 144 h in hypoxic conditions. Columns 
and bars, mean values±S.E., respectively. *P < 0.001 vs. vehicle-treated controls. F. ABCG2 protein level in 231/LM2-4 cells exposed to 
metronomic topotecan, pazopanib, sunitinib or combinations thereof, or with vehicle alone for 144 h in hypoxic conditions. 
Figure 2: Proapoptotic effects of topotecan (TPT) and pazopanib (PZ) on proliferating 231/LM2-4 cells treated for 
144h in hypoxic conditions. Apoptosis measurements using the Cell Death Detection ELISA Plus kit (Roche Diagnostics). Percentage 
Absorbance values are representative of 231/LM2-4 cytosolic nucleosomes. The experiment was repeated 3 times with a least 2 replicates 
per sample. Columns and bars, Mean values±S.E., respectively. *, P < 0.001 vs. vehicle-treated controls. Small error bars are not visible 
in the graph.
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that at extracellular topotecan concentrations of 1 µM, 
intracellular accumulation of topotecan is significantly 
higher (approximately 50%) if the chemotherapeutic 
drug is co-administered with pazopanib or sunitinib 
in 231/LM2-4 (Figure 1D; 0.024±0.008 (100%) vs. 
0.035±0.022 (141%) and 0.036±0.014 (146%) ng/µg 
protein, respectively; P < 0.001), in MDA-MB-231 
(Supplementary Figure 2A) and in endothelial cells 
(Supplementary Figure 2B and 2C). 
Based on these findings, we investigated the 
variation of ABCG2 expression; the gene expression and 
the protein levels of this transporter were quantified in 
cancer and endothelial cell lines exposed to the different 
drugs at the experimental IC50 in hypoxic conditions. 
Similar to HIF1α, Figure 1E shows a significant decrease 
of ABCG2 gene expression in 231/LM2-4 hypoxic-
treated cells, by the concurrent combination of either 
TKI and metronomic topotecan (topotecan + pazopanib 
daily exposure 23±2.57% and topotecan + sunitinib daily 
exposure 16±1.43% vs. 100% of control expression; P 
< 0.001). Moreover, the combination of the two drugs 
showed a decrease of ABCG2 protein level (Figure 1F) 
when compared to the single drugs alone, as demonstrated 
by Western blot analysis.
 Moreover, the significantly decreased levels of 
HIF1α was associated with the decrease of its target genes 
CA9 (data not shown), VEGF (Supplementary Figure 3) 
by the treatment combination of metronomic topotecan 
and pazopanib in 231/LM2-4 and endothelial cells grown 
under hypoxic conditions.
The combination of topotecan and pazopanib or 
sunitinib enhances tumor cell apoptosis
The possible impact of the enhanced intracellular 
topotecan retention caused by pazopanib co-treatment 
on tumor cell apoptosis was investigated by assessing 
the mono- and oligonucleosomes in the cytoplasmic 
fraction of cell lysates and by bromodeoxyuridine 
(BrdU) incorporation. The extent of DNA fragmentation 
was increased by the combination of both drugs. In 
particular, the presence of chromatin fragments was 
clearly detectable after 144 h for pazopanib and topotecan, 
alone and in combination at their IC50 concentrations. As 
shown in Figure 2, after 144 h treatment with pazopanib 
and topotecan (in hypoxic conditions) a significantly 
higher percentage of apoptotic cells in the treated samples 
was found when compared to vehicle-treated cells. 
Furthermore, the same pro-apoptotic effects of pazopanib 
and topotecan, alone and in combination, were observed 
also in endothelial cells (HUVECs) at lower concentrations 
(Supplementary Figure 4). The increase of apoptotic 
cells was observed also after bromodeoxyuridine (BrdU) 
incorporation. The addition of pazopanib to metronomic 
topotecan induced an increase in the percentage of 231/
LM2-4 BrdUrd-unlabeled cells, compared to controls 
(data not shown). 
In vivo therapy: effects of single agent topotecan 
administered as MTD (maximum tolerated dose) 
or low-dose metronomic schedule (LDM) in 
combination with pazopanib on localized primary 
breast tumors
We first tested topotecan and pazopanib on primary 
orthotopic implanted 231/LM2-4 tumors. We assessed 
tumor growth in six different treatment groups: vehicle 
control, LDM topotecan, MTD topotecan, and the doublet 
combination of LDM/MTD topotecan and pazopanib. As 
shown in Figure 3A and 3B, single-agent LDM and MTD 
topotecan did not have any significant antitumor effect. In 
contrast, the LDM topotecan and pazopanib combination 
caused a significant tumor growth delay (e.g. at day 35, 
384.01 mm3 vs. 1488.5 mm3 of controls, P < 0.05), greater 
than that observed with the MTD combination (619.59 
mm3). The toxicity profile showed that mice treated with 
the LDM combination schedule maintained stable body 
weight throughout the course of the experiment, whereas 
in the MTD combination treatment group a tumor growth 
delay was detected in parallel with fluctuating weight loss 
(e.g. at day 35, 17.82±1.04 g vs. 20.46±0.31 g of controls, 
P < 0.05) (Figure 3C). Mice treated with 0.1% HPMC 
(vehicle control) and 1 mg/kg/day LDM topotecan had to 
be sacrificed at day 39 and 32, respectively, due to tumor 
size reaching 1.7 cm3. 
Staining for Ki67, a marker of cell-cycle progression 
and proliferation, showed a remarkable decrease in 
231/LM2-4 tumors after MTD and LDM combination 
treatments (Figure 3D). Basal levels of caspase-3 activity 
detected in tumor samples from control mice were not 
modified by pazopanib treatment but, conversely, they 
were increased in the group treated with LDM and MTD 
topotecan alone. Moreover, the highest significant increase 
of caspase-3 activity was observed when mice were treated 
daily with oral topotecan plus concurrent pazopanib 
(Figure 3E). Thus, the in vivo prolonged exposure of 
tumor cells to MTD/metronomic doublet translates into a 
significant increase in tumor cell apoptosis. Furthermore, 
CD31 staining in tumor sections from control, LDM and 
MTD topotecan treated animals showed a similar presence 
of number of vessels, which instead were statistically 
decreased in mice treated with pazopanib alone and in 
combination with both LDM and MTD topotecan (Figure 
3F).
To evaluate the in vivo relationship between HIF1α 
and ABCG2 and their potential roles in the mechanisms 
involved in the activity of the treatment combination 
of topotecan with pazopanib, a different experiment 
on primary tumors was carried out. The 231/LM2-4 
variant was injected into MFPs of female SCID mice (n 
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Figure 3: In vivo antitumor effects of the single drugs and simultaneous combination of maximum tolerated dose 
(MTD) or low-dose metronomic (LDM) topotecan (TPT) and pazopanib (PZ) schedules on 231/LM2-4 tumours 
xenotransplanted in mice: tumor growth curve A. % T/C value B. and body weights of mice C. P < 0.05 vs. control. Quantification 
of Ki67 D. Capase-3 E. and CD31 F. in 231/LM2-4 tumour xenografts administered with vehicle, oral topotecan (LDM) at 1 mg/kg daily 
by gavage, MTD topotecan 1.5 mg/kg 5 days consecutively every 3 weeks through i.p. injection, pazopanib 150 mg/kg by gavage daily 
without interruption and their combinations. Symbols/columns and bars, mean values±S.D., respectively. 
Figure 4: A. Tumor growth curve of the single drugs and simultaneous combination of topotecan (TPT) and pazopanib (PZ) schedules 
in 231/LM2-4 tumour xenografts administered for 14 days with vehicle, oral low-dose metronomic (LDM) topotecan at 1 mg/kg daily by 
gavage, maximum tolerated dose (MTD) topotecan 1.5 mg/kg 5 days consecutively every 3 weeks through i.p. injection, pazopanib 150 mg/
kg by gavage daily without interruption, and their combinations. P < 0.05 vs. vehicle-treated controls. B. and C. HIF1α and ABCG2 gene 
expression in tumor samples, respectively. Columns and bars, mean values±S.E., respectively. 
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= 5 animals per group). When primary tumors reached 
a size of 150 mm3, treatment with topotecan LDM 1 
mg/kg/day and MTD 1.5 mg/Kg, pazopanib 150 mg/
Kg/day was initiated. After three weeks animals were 
sacrificed and tumors were excised (Figure 4A). Figure 
4B and 4C showed gene expression inhibition of HIF1α 
and ABCG2, respectively, in tumors induced by both the 
MTD and LDM topotecan plus pazopanib concurrent 
drug combination. The outcomes observed using the two 
different types of combined treatment protocols were 
statistically significant when compared with the single 
administration of topotecan both in MTD and LDM (P < 
0.001 vs. control). 
Survival of mice with advanced metastatic disease
In the experiment involving treatment of advanced 
metastases the MDA-MB-231/LM2-4 variant was injected 
orthotopically (n = 5 mice per group) and impact on 
survival was assessed. When tumors reached 400 mm3 
primary tumors were surgically resected. Treatment was 
initiated at day 39, nineteen days post primary tumor 
resection. A Kaplan-Meier survival curve was plotted 
accordingly for all treated groups is shown in Figure 5. 
Using survival as the end point, 1 mg/kg/d LDM topotecan 
therapy alone, pazopanib 150 mg/kg/d monotherapy and 
MTD topotecan plus 150 mg/kg/d pazopanib group did 
not have any significant effect on survival of the mice; 
the MTD topotecan group showed a small effect in 
prolonging survival. In marked contrast, the chronic 
metronomic combination treatment (1 mg/kg/d topotecan 
+ 150 mg/kg/d pazopanib) greatly prolonged survival 
of the mice. Median survival values were as follows: 66 
days for control, 56 days for LDM topotecan, 84 days 
for MTD topotecan, 66 days for Pazopanib, 63 days for 
MTD topotecan and Pazopanib, and 145 days (P = 0.0057 
vs. control) for LDM topotecan + pazopanib. Notably, 
our data in the two different models demonstrated that 
the treatment efficacies in the primary tumours did not 
necessarily predict for analogous effects in the metastatic 
setting. Indeed, primary tumor growth reduction was 
observed (Figure 3A) following LDM or MTD topotecan 
and pazopanib therapy, but in the advanced metastatic 
model, only LDM topotecan and pazopanib treated mice 
had a significant improved overall survival (Figure 5). 
Effects of single agent topotecan administered 
as MTD versus metronomic compared to 
combination with sunitinib on growth of localized 
breast primary tumors 
In an experiment involving primary tumors in 
mice treated with sunitinib we assessed tumor growth 
using six different regimen groups, as described above. 
As shown in Figure 6A and 6B, single-agent LDM and 
MTD topotecan did not have any antitumor effect. In 
contrast, LDM topotecan plus sunitinib caused a greater 
tumor growth delay (e.g. at day 28, 200.17 mm3 vs. 1372.6 
Figure 5: Effect on survival caused by low-dose metronomic (LDM) oral topotecan (TPT) alone or in combination 
with pazopanib (PZ). The drug treatments and doses tested were: vehicle control, maximum tolerated dose (MTD) topotecan (1.5 mg/
kg i.p. 5 consecutive days every 3 wk), LDM oral topotecan (1 mg/kg by gavage, daily), pazopanib once a day (150 mg/kg by gavage 
daily), pazopanib once a day + LDM topotecan or MTD topotecan. Mice were euthanized when more than 20% body weight loss occurred 
or when moribund and then assessed; n = 5 mice for all groups. Kaplan-Meier P < 0.05 was taken as statistical indication of difference vs. 
vehicle-treated controls.
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mm3 of controls; P < 0.001), greater than that obtained 
using the MTD drug combination (400 mm3). The 
combination of LDM topotecan and sunitinib showed, 
although not significant, a slight decrease of Ki67 (+) 
cells (Figure 6C). Moreover, samples from treated and 
control mice were analyzed by immunohistochemistry 
for cleaved caspase-3 expression. Comparisons of 
stained cells normalized to mm2 of tumor area revealed 
significant increase of cleaved caspase-3 expression in the 
metronomic combination (Figure 6D; P < 0.05). Changes 
in the gene expression profile of HIF1α and ABCG2 were 
noted within each group of treated mice. The combination 
schedule, both LDM and MTD, significantly decreased 
HIF1α and ABCG2 gene expression (Figure 6E and 6F; P 
< 0.001 vs. control and vs. the single drug administration, 
respectively).
DISCUSSION
 Perception of the impact and benefits of 
antiangiogenic drugs for the treatment of breast cancer 
remains controversial [31, 32]. On the one hand positive 
phase III clinical trial results with respect to progression 
free survival (PFS) have been reported with bevacizumab 
in combination with various chemotherapy regimens as 
first line (upfront) therapies in the metastatic setting [31-
33] and as a maintenance therapy in a phase III trial where 
a benefit in overall survival (OS) was also reported in a 
trial called IMELDA [34]. Neoadjuvant bevacizumab plus 
chemotherapy also caused increases in pathologic response 
rates (pCR) in triple negative breast cancer patients [35, 
36]. On the other hand the disease free survival results 
of several adjuvant therapy trials evaluating bevacizumab 
plus chemotherapy followed by bevacizumab maintenance 
in early stage breast cancer patients have been 
disappointing despite a clear initial benefit while patients 
receive treatment, and for a period after the maintenance 
treatment is stopped [31, 37]. However, a recent phase III 
trial of neoadjuvant bevacizumab followed by adjuvant 
bevacizumab plus chemotherapy (NSABP-B40) reported 
benefits in PFS and OS in hormone positive-receptor 
breast cancer patients in secondary analyses [38]. Finally, 
all phase III trials evaluating an oral antiangiogenic TKI 
plus standard chemotherapy in metastatic breast cancer 
Figure 6: A. Effect of low-dose metronomic (LDM) oral topotecan (TPT) alone or in combination with sunitinib (SU). 231/LM2-4 human 
breast cancer cells were injected i.p. into SCID mice. Treatments were initiated 14 day after tumor injection. The drug treatments and 
doses tested were: vehicle control, maximum tolerated dose (MTD) topotecan (1.5 mg/kg i.p. 5 consecutive days every 3 wk), LDM oral 
topotecan (1 mg/kg by gavage, daily), sunitinib once a day (60 mg/kg by gavage daily), sunitinib once a day + LDM topotecan or MTD 
topotecan. B. % T/C value. Quantification of Ki67 C. and Capase-3 D. levels. Symbols/columns and bars, mean values±S.D., respectively. 
E. and F. HIF1α and ABCG2 gene expression in tumor samples, respectively. Columns and bars, mean values±S.E., respectively. *P < 
0.001 vs. vehicle-treated controls.
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patients have been negative [32, 33, 37].
With this background in mind, it would seem that 
VEGF pathway targeting drugs have anti-tumor activity, 
albeit limited, against breast cancer in many circumstances, 
and as such, provides a rationale for devising strategies 
to improve their impact. Such strategies include reducing 
toxicity using new treatment combinations (especially 
incorporating less toxic chemotherapy ‘backbone’ 
regimens), uncovering promising predictive markers to 
help select patients more likely to benefit from receiving 
an antiangiogenic therapy, and developing improved 
preclinical models to evaluate new treatment possibilities. 
One such preclinical model involves treatment of mice 
with advanced metastatic breast cancer, not just primary 
tumors [39, 40]. As an example, we previously reported 
that antiangiogenic drugs, including pazopanib or sunitinib 
were ineffective in treating mice with advanced metastatic 
human triple-negative breast cancer, even when combined 
with conventional cytotoxic MTD chemotherapy, whereas 
the antiangiogenic drugs could cause inhibition of primary 
tumor growth [41]. However, it has been also described 
that the antiangiogenic therapy, while blocking tumor 
volume growth, was found to increase local invasion 
in multiple primary tumor models, but this effect was 
blocked by concurrent chemotherapy [42, 43]. These 
data suggest that the therapeutic impact of antiangiogenic 
drugs may vary in different tumor models, and that 
anti-VEGF-A therapy can block the invasion properties 
of tumor cells in response to chemotherapy [44]. Our 
metastatic model therapy results recapitulated prior 
phase III clinical trial outcomes using sunitinib-based 
regimens to treat metastatic breast cancer patients [41]. 
We therefore decided to evaluate sunitinib or pazopanib 
in such metastatic versus conventional primary models 
in combination with chemotherapy using a low-dose 
metronomic chemotherapy (topotecan) protocol which 
has previously shown excellent therapeutic results 
in other preclinical models including ovarian cancer 
[16, 17], sarcomas [18] and renal cell carcinoma [20], 
and investigate mechanisms of action involved in the 
antitumor activity of this treatment combination.
Triple negative breast cancer has a highly aggressive 
nature with very limited treatment options and carries a 
very poor prognosis [30]. A single accepted standard 
chemotherapy regimen for patients with TNBC is not 
currently available, and thus treatment is selected from 
recommended agents approved for metastatic disease (i.e. 
chemotherapeutic regimens containing anthracyclines, 
and taxanes alone or in combination with bevacizumab) 
[30, 45]. Therefore new and more effective therapies for 
patients affected by this breast cancer subtype are urgently 
needed [30]. The impact of pazopanib in the treatment 
of breast cancer will be better known in the near future 
because of ongoing trials which involve the combination 
of this TKI with various chemotherapy regimens [23, 
24]. However, one important issue concerning such 
combination treatments will likely be the tolerability of 
administering a TKI such as pazopanib with standard-of-
care cytotoxic chemotherapy agents. Although pazopanib 
at 800 mg was shown to be safely combined with weekly 
paclitaxel at 80 mg/m2, other chemotherapy regimens 
resulted in dose reductions of pazopanib [46]. In this 
regard, low dose, less toxic metronomic chemotherapy, 
which has shown efficacy in patients with metastatic breast 
cancer in limited phase II clinical studies [47], could be 
a feasible combination approach to limit the toxicity of 
pazopanib or other TKIs and enhance efficacy. 
 In our study we report, for the first time to our 
knowledge, the remarkable efficacy of the metronomic 
topotecan and pazopanib treatment combination, 
especially in the metastatic triple negative breast cancer 
model, which caused a significantly prolonged survival 
times. Although a possible limitation of our study 
concerns the employment of a metastatic model using a 
single cell line (i.e. LM2-4), the choice of this metastatic 
variant subline derived from the human triple negative 
breast cancer cell line MDA-MB-231, was based on its 
capability to give rise to extensive systemic spontaneous 
metastases in multiple sites such as the lungs, liver 
and lymph nodes within one month after resection of 
the primary orthotopic tumour in SCID mice [40]. As 
previously reported, responses of primary tumours are 
not necessarily indicative of the effects of the same 
treatment strategies when use to treat metastatic disease 
[41, 48]. Indeed, our results showed that both the LDM or 
MTD combinations of topotecan and pazopanib improve 
primary tumour response compared to the single drugs 
alone. However, only the metronomic combination was 
highly efficacious against metastatic disease, highlighting 
the potential benefit of using metronomic chemotherapy in 
combination with an antiangiogenic drug during late stage 
disease settings. 
What are the possible underlying mechanisms 
responsible for these encouraging effects? Topotecan 
when administered in a metronomic-like fashion was 
previously reported to potently inhibit HIF1α translation 
by a DNA damage-independent mechanism [49]. When 
administered in a low-dose, continuous schedule it blocks 
the expression of tumor cell HIF1α, as first described 
by Melillo’s group [50]. HIF1α has a central role in 
regulating a broad spectrum of genes involved in tumor 
angiogenesis, invasion, and metastasis [51, 52]. Thus, 
exposure of tumor cells to metronomic topotecan causes a 
decreased expression of VEGF, likely as a result of HIF1α 
downregulation [5]. As previously reported, the addition 
of a low dose daily topotecan protocol with bevacizumab 
significantly inhibited tumor growth in glioblastoma 
xenografts, when compared to mice treated with topotecan 
or bevacizumab alone [49]. In our in vitro experiments we 
showed the ability of low-dose metronomic oral topotecan 
alone to suppress HIF1α in cells under hypoxic conditions. 
However, in our breast cancer model no significant 
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antitumor effect on primary tumors was observed and 
neither prolonged survival was noted. Indeed, even 
though LDM topotecan could have its therapeutic effects 
increased in a hypoxic-stressed tumor microenvironment, 
in our study, the administration of this drug alone in either 
primary or metastatic breast cancer therapy models did 
not translate into a therapeutic advantage. One possible 
explanation for these findings may be the level of ABCG2 
expression, a known and effective resistance mechanism 
of mammary tumors enabling them to evade topotecan-
induced DNA damage [53]. Indeed, in our study the 
metronomic topotecan treatment regimen decreased 
ABCG2 expression, as shown in Figure 2, but the level 
of this inhibition was likely not enough to neutralize the 
effects of the transporter on the drug in vivo, and thus 
lowering the intracellular concentrations of topotecan. 
Studies on ABCG2 transporter have revealed three 
hypoxia-response elements in the ABCG2 promoter, 
suggesting that its expression is likely regulated by the 
hypoxia - HIF1α pathway -, that results in modulation 
of its expression [54], enhancing cell survival [55]. 
Considering the possibility that HIF1α activation 
may strongly influence ABCG2 upregulation and that 
the level of HIF1α expression is not the same in all 
tumors, we evaluated whether sunitinib or pazopanib 
could enhance the action of an HIF1α inhibitor such as 
topotecan. The results of our experiments showed the 
significantly decreased levels of HIF1α and its target 
genes - CA9 (data not shown), VEGF and ABCG2 - by 
the treatment combination of metronomic topotecan and 
pazopanib in 231/LM2-4 or endothelial cells grown under 
hypoxic conditions. Moreover, this treatment protocol 
caused significant tumor growth delays and greatly 
prolonged survival times of the mice together with a 
significant decreased HIF1α/ABCG2 gene expression in 
tumors, when compared with the single drug treatments, 
suggesting the use of the combination schedule treatment. 
Similar changes in the expression of HIF1α and ABCG2 
were also noted in 231/LM2-4 hypoxic-treated cells and 
tumors treated with topotecan and sunitinib. Simultaneous 
treatment of these drugs markedly reduced expression of 
these genes relative to either agent alone, explaining the 
high degree of efficacy of the combination compared to 
the weak or no-effects of LDM topotecan alone. 
Interestingly, various TKIs have also been 
described as competitive inhibitors of ABCG2 [56]. 
Imatinib mesylate - a substrate for ABCG2 - can reverse 
resistance to irinotecan acting as such a competitive 
ABCG2 inhibitor [57]. Our group (T.D.D. and G. B.) 
previously suggested that the combination of axitinib 
and SN38, the active metabolite of irinotecan, increased 
intracellular accumulation of SN38, by axitinib-mediated 
inhibition of ABCG2 [58]. Sunitinib was found to inhibit 
transport mediated by ABC drug transporters, which 
may affect the bioavailability of drugs which are co-
administered [56]. Pazopanib, instead, seems to be a high 
affinity substrate for this carrier, as previously described 
[25]. Pazopanib could itself be a substrate of ABCG2 
and thus mediates a pharmacodynamic interaction with 
LDM topotecan, resulting in a competitive inhibitory 
mechanism at the level of topotecan extrusion from the 
cancer cell mediated by ABCG2. Thus, the results of our 
study suggest that combining low dose topotecan with 
TKIs that are substrates of common ABC transporters 
might downregulate, saturate or inhibit the transporter 
and increase anticancer activity. Indeed, our in vitro data 
clearly show that the combination of low dose topotecan 
with pazopanib significantly increase intracellular levels of 
active topotecan in cancer cells, enhancing the antitumor 
effects of the combination [20]. 
Since ABC transporters are also involved in the 
disposition of most drugs, pharmacokinetic interactions 
may considerably complicate successful application 
of combination therapies in the clinic [53]. The 
pharmacokinetic and pharmacodynamic changes that 
can occur when chemotherapeutic drugs at standard 
doses are combined with TKIs may allow to exploit 
the aforementioned advantage of LDM topotecan 
therapy in a hypoxic-stressed tumor microenvironment. 
In this regard, our data showed no changes in mouse 
body weight associated with metronomic topotecan 
combination regimens, in contrast with the MTD-based 
regimens. Moreover, in a clinical study in patients with 
gynecological cancers treated with this combination drug 
schedule, no dose adjustment was necessary for low 
dose topotecan, suggesting a good toxicity profile of the 
combination of metronomic topotecan and pazopanib [21].
Although at first glance it could appear that there 
is only a small difference in topotecan dose between the 
two administered schedules (LDM 1.0 mg/kg p.o. daily vs. 
MTD 1.5 mg/kg i.p. for 5 days every 3 weeks), the route of 
administration is fundamental to understand the different 
active plasma concentrations reached by the LDM and 
MTD protocols. Indeed, as previously demonstrated in a 
topotecan pharmacokinetic study, after oral administration 
the maximal plasma concentration (Cmax) of the active 
lactone was 10-fold less than that reached after i.p. drug 
administration [59]. Therefore the oral administration 
and the dose fractionation of the metronomic protocol 
determines low concentrations of the active drug, and thus 
an improved toxicity profile, suggesting its possible use 
for future clinical trials.
Another interesting finding of our study is that 
pazopanib, sunitinib and topotecan all cause a direct 
cytotoxic effect on cancer and endothelial cells, as shown 
by the combined IC50. In vivo, cancer cell proliferation has 
been measured by immunohistochemical analyses of Ki67, 
a nuclear marker expressed in all phases of the cell cycle 
except G0 [60]. The expression of Ki-67 is one of the most 
reliable indicators of the proliferative status of cancer cells 
and is closely associated with the growth and invasion of 
breast cancer [61]. In our experiments the number of Ki-
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67-positive cells in tumors obtained from LDM topotecan 
plus pazopanib-treated mice was 48% lower than found in 
the control group. Although these data were obtained from 
tumor tissue samples taken at different time points, in our 
in vivo study on primary tumors - treated with topotecan 
and pazopanib (Figure 3) - the Ki67 staining was 
performed approximately two weeks after the beginning 
of the second cycle of MTD administration. Rapid tumor 
cell repopulation can take place between successive 
MTD chemotherapy treatments, but in this experiment 
Ki67+ cells were not increased in MTD chemotherapy-
treated tumors, suggesting that probably tumor regrowth/
repopulation during the chemotherapy break period might 
be more evident after 3 weeks from the beginning of the 
MTD therapy. 
Moreover, in our in vitro experiments, we were 
able to show that pazopanib triggers apoptosis in 231/
LM2-4 cells, which was much more pronounced by 
this orally available drug under hypoxic conditions. In 
agreement with these findings, low-dose combination 
treatments were able to significantly increase the activity 
of caspase-3 expression compared to controls, as noted in 
in vivo models. Caspase-3-like protease is involved in the 
apoptotic death of MDA-MB-231 and 231/LM2-4 cells 
[62]. The combinations of LDM topotecan and pazopanib 
were associated with marked and significantly higher 
rates of cancer cell apoptosis and resulted in significant 
decreased levels of vessel density, assessed by CD31 
staining.
In conclusion, the combination pazopanib/
metronomic topotecan regimen was particularly effective 
in the metastatic triple-negative breast cancer model 
including causing a significanting prolonged survival with 
a favourable toxicity profile. Also noted were marked 
decreases in tumor volume, vascularity and proliferative 
index, associated with the downregulation of HIF1α 
and ABCG2, and increased intracellular concentrations 
of active topotecan. Furthermore, these changes were 
highly dependent on growth of the cells under hypoxic 
conditions when assessed in vitro. Also noteworthy were 
the differences in therapeutic outcomes in the various 
mice treatment groups when therapy was undertaken in 
mice with primary tumors versus advanced metastatic 
disease, as also previously discussed by Francia and 
colleagues [39]. These findings suggest the possibility of 
the use of low dose metronomic topotecan in combination 
with pazopanib, or similar drug combinations involving 
a topoisomerase-I poison with an antiangiogenic drug 
(e.g. antibodies such as bevacizumab or ramucirumab), as 
novel and potential therapeutic options for the treatment of 
triple-negative metastatic breast cancer.
MATERIALS AND METHODS
Materials, drugs and cell lines
The details of materials, drugs and cell lines used 
in the experiments are reported in the Supplementary 
Materials and Methods.
In vitro studies
In vitro assessment of cell proliferation inhibition 
by topotecan, pazopanib and their combination on triple 
negative breast cancer cell line MDA-MB 231 cell line 
[63, 64] and its highly metastatic variant called MDA-
MB 231/LM2-4 [40] and on endothelial cells for 72h [65] 
and 144h [58] was performed by CellTiter 96® AQueous 
One Solution Cell Proliferation Assay (MTS; Promega) 
[66]; apoptosis measurements were made by Cell Death 
Detection ELISA Plus kit (Roche Diagnostics, Laval, QC, 
Canada) and bromodeoxyuridine (BrdU) incorporation 
analysis; HIF1α and ABCG2 gene expression was 
obtained with Real-time PCR analysis and their protein 
levels evaluation was performed by Western Blot assay; 
intracellular accumulation of topotecan was measured 
by HPLC analysis as previously described [67, 68]. 
The details of these experiments are reported in the 
Supplementary Materials and Methods.
In vivo studies
Animals and treatments
Six-week-old in house bred female YFP SCID mice 
were housed in microisolator cages on vented racks and 
manipulated using aseptic techniques. MDA-MB 231/
LM2-4 is a variant cell line of MDA-MB 231 selected in 
vivo for aggressive spontaneous metastatic spread from 
established but resected primary tumors and was grown 
in cell culture as previously described [40]. Mammary 
fat pad (MFP) orthotopic injection (2×106 cells) was 
carried out as previously described [40]. Weekly caliper 
measurements were carried out to determine tumor growth 
and tumor volume. Tumor volume (mm3) was defined 
as follows: [(w1 x w1x w2) x (π/6)], where w1 and w2 
were the smallest and the largest tumor diameter (mm), 
respectively. Treatment of primary tumors (n = 5 mice per 
group) was initiated when the average volume was in the 
range of 100 - 150 mm3. All mice were randomized just 
before initiation of treatment. In the survival experiments 
(n = 5 mice per group), surgical resection of the primary 
tumors was carried out when the average tumor size was 
around 400 mm3. Control mice received either vehicle 
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and/or normal saline as appropriate. Pazopanib, sunitinib 
and topotecan or their simultaneous combinations 
using conventional and metronomic schedules were 
administered as follows: LDM topotecan LDM was 
given at 1 mg/kg daily by gavage [20]; MTD topotecan 
was given at 1.5 mg/kg 5 days consecutively every 3 
weeks via i.p. injection [16]; pazopanib 150 mg/kg was 
administered by gavage daily without interruption; 
sunitinib was administered by gavage at 60 mg/kg dose 
daily. Each experiment employed the minimum number of 
mice needed to obtain statistically meaningful results. At 
termination tumors were excised, measured and sampled 
for gene expression and immunohistochemistry. Drug 
efficacy was based on percentage of the average treated-
tumour-volume divided by the average vehicle-control-
tumour-volume (% T/C) [69].
Immunohistochemistry
Tumor tissue samples in the primary tumor 
experiments with topotecan and pazopanib were taken 
at different time points, when tumors in mice of each 
group reached their respective volume endpoints. The 
end of the experiment for each group was as follows: i) 
control group, day 39; ii) LDM topotecan, day 32; iii) 
MTD topotecan, day 53; iv) pazopanib, day 59; v) LDM 
topotecan + pazopanib, day 59; vi) MTD topotecan + 
pazopanib, day 59. Instead, in the case of topotecan and 
sunitinib, all samples were taken at day 28, at the end of 
the experiment. Briefly, tumor tissue samples from all 
the different treatment groups were fixed in 10% neutral-
buffered formalin for 24 h, processed and embedded 
in paraffin for histology and immunohistochemistry. 
Formalin-fixed and paraffin-embedded samples were 
firstly cut into 5-μm-thick sections. The antigen retrieval 
was accomplished by deparaffinization, rehydration, and 
heating in a microwavable pressure cooker with citrated 
buffer; 3% hydrogen peroxide diluted in water was used 
to block the endogenous peroxidase activity and BSA 
was used to block nonspecific staining. Sections were 
incubated with rabbit PECAM-1 antibody (M-20) (1:200, 
#sc1506, Santa Cruz Biotechnology), rabbit anti-Ki67 
antibody (1:1000, #VPK451, VECTOR Lab) and rabbit 
anti-cleaved Caspase-3 (Asp175) (1:300, #9664, Cell 
Signaling) at 4°C overnight. Negative controls were 
carried out by omitting the primary antibodies. The LSAB 
+ System HRP Kit (DAKO, Mississauga, ON, Canada) 
was used to detect primary antibody followed by staining 
with DAB reagent and counterstaining with hematoxylin. 
Sections were visualized under a Carl Zeiss Axioplan 2 
microscope (Carl Zeiss Canada Inc) and images captured 
with a Zeiss Axiocam digital camera controlled by 
AxioVision 3.0 software.
Real-time PCR and western blot analysis of 
HIF1α and ABCG2 on tumor tissue samples
Tumor tissues (from primary tumors) were 
homogenized using the gentleMACS™ Dissociator 
(Miltenyi Biotec, San Diego, CA, USA). Total RNA was 
extracted from tumor tissue samples by using the RNEasy 
kit mini (Qiagen, Mississauga, ON, Canada) following 
manufacturer’s instructions. Human HIF1α and ABCG2 
gene expression and protein levels evaluation in tumor 
samples was performed as described in Supplemental 
materials and methods. 
Statistical analysis
The results of all in vitro experiments were subjected 
to analysis of variance among groups (ANOVA), followed 
by the Student-Newman-Keuls test. Tumor therapy results 
are reported as mean±S.D. Survival curves were plotted 
by the method of Kaplan and Meier and were tested for 
survival differences using the log-rank test. The level of 
significance was set at P < 0.05. Statistical analyses were 
performed using the GraphPad Prism software package 
version 5.0 (GraphPad Software, Inc, San Diego, CA).
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Potent efficacy of metronomic topotecan and pazopanib combination 
therapy in preclinical models of primary or late stage metastatic triple-
negative breast cancer 
Supplementary Materials and Methods 
Materials and drugs  
Recombinant human vascular endothelial growth factor (rhVEGF) and recombinant human 
epidermal growth factor (rhEGF) were purchased from R&D Systems Inc. (Minneapolis, MN, 
USA). MCDB131 medium, type A gelatin from porcine skin, supplements and all other 
chemicals not listed in this section were purchased from Sigma-Aldrich (Oakville, ON, Canada); 
RPMI 1640 medium (Hyclone) and fetal bovine serum (FBS) (Hyclone, Logan, Utah) were 
purchased from Fisher Scientific (Markham, ON, Canada); horse serum (HS), L-glutamine, 
penicillin, streptomycin, antibiotics were from Life Technologies (Burlington, ON, Canada). 
Tissue culture plasticware (Nunc, Thermo Scientific) were supplied by VWR (Mississauga, ON, 
Canada). Topotecan, pazopanib, and the pazopanib vehicle, hydroxypropylmethyl cellulose, 
were supplied by GlaxoSmithKline. Sunitinib was purchased  from LC Laboratories, Woburn, 
MA, USA. For the in vitro experiments the drugs were dissolved in DMSO and diluted as 
needed; for in vivo studies these drugs were reconstituted as per the manufacturer's 
instructions.   
Cell lines  
Human Umbilical Vein Endothelial Cells (HUVECs) and Human Dermal Microvascular 
Endothelial Cells (HMVEC-d) were purchased from Clonetics (San Diego, CA) and maintained in 
MCDB131 medium supplemented with antibiotics, 10% heat-inactivated FBS, L-glutamine (2 
mM), heparin (10 IU/ml), rhEGF(10 ng/ml) and bFGF (5 ng/ml). The human triple-negative 
breast cancer cell line MDA-MB-231 [64] was obtained from Jeff Lemontt (Genzyme) and 
maintained in RPMI1640, supplemented with 5% FBS. A highly metastatic variant of MDA-MB-
231, called 231/LM2-4, isolated in vivo as previously described [40] was cultured in RPMI 1640 
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supplemented with 5% fetal bovine serum. All the in vitro experiments, for the exceptions of 
cell proliferation assays, were performed in hypoxic (1% (v/v) O2, 5% (v/v) CO2, 95% humidity) 
conditions. Cells were cultured under normoxic conditions (20% O2, 5% CO2, 95% humidity) 
until 70%–80% confluent, and were then switched to hypoxic conditions (1% O2, 5% CO2, 95% 
humidity) in an Invivo2 hypoxia chamber (Ruskinn Technologies). 
Animals 
In house bred female YFP severe combined immunodeficient (SCID) mice were  used for all in 
vivo experiments. The Sunnybrook Research Institute Animal Care Committee (SRI ACC) has 
approved the in vivo study. The procedures involving animals and their care were conducted in 
strict conformity with the animal care guidelines of Sunnybrook Research Institute and the 
Canadian Council of Animal Care (CCAC). 
Cell line authentication 
Cell line authentication was carried out by genotyping, and the cells were confirmed to be 
human in origin. All human cell lines used in this publication were processed by Genetica DNA 
Laboratories (a LabCorp Specialty Testing Group; Burlington, NC) for authentication testing 
using analytical procedures for DNA extraction, PCR and capillary electrophoresis on a 3130xl 
genetic analyzer (Applied Biosystems). The thirteen core CODIS short tandem repeat (STR) loci 
plus PENTA E and PENTA D, and the gender-determining locus, amelogenin, were analyzed 
using the commercially available PowerPlex® 16HS amplification kit (Promega Corporation) 
and GeneMapper ID v3.2.1 software (Applied Biosystems).  Appropriate positive and negative 
controls were used concurrently throughout the analysis.  Authentication of each cell line was 
confirmed by entering the STR DNA profile of each tested cell line into known repository cell 
line databases [i.e. ATCC, DSMZ, etc]; authentication is defined as having a percent match with 
the reference STR profile at or above 80% when using the ANSI/ATCC guidelines (ASN-0002-
2011) OR having a “unique” STR DNA profile (no matches found) for “in-house” cell lines not 
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distributed by any cell line repository. Routine mycoplasma screening was carried out in-house 
using commercial kit (MycoAlert Detection Kit, Lonza, Mississauga, ON, Canada), which 
confirmed the cell line was mycoplasma free. 
Cell proliferation assay 
HUVECs, HMVEC-d (1 x 103 cells/well) and 231/LM2-4 (1 x 10.53 cells/well) cells were plated in 
24-well plates (1% gelatin-coated for HUVEC and HMVEC-d) and allowed to attach overnight. 
Cells were treated with pazopanib (0.01-1000 nM), sunitinib (0.01-1000 nM) and topotecan 
(0.001-1000 nM), alone or in combination, or with their respective vehicles continuously for 
144 h in 0.1 ml of medium, adding fresh medium and drug every 24 h to mimic continuous 
metronomic treatment [61]. In separate experiments, cells were treated with pazopanib (0.01-
1000 nM), sunitinib (0.01-1000 nM) and topotecan (0.001-1000 nM), alone or in combination, 
or with their respective vehicles for 72 h to mimic maximum tolerated dose (MTD) treatment 
[58]. At the end of treatments, the cells were harvested with trypsin/EDTA, and the viable ones 
counted with a hemocytometer. Cell viability was assessed by trypan blue dye exclusion. The 
data are presented as the percentage of the vehicle-treated cells [58]. An additional method 
for determining the number of viable cells undergoing proliferation was performed. 
Endothelial and tumor cell lines were plated in 96-well plates (6 x 102 cells) and treated, as 
previously described, for 72h or continuously for 144 h [65]. Proliferation assays were 
performed using CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS; Promega) 
according to manufacturer’s instructions [66]. All the experiments described were performed 
both in normoxic conditions. Values were expressed relative to vehicle-treated cells. The 
concentration of drugs that decreased cell proliferation by 50% (IC50) as compared to controls 
was calculated by non-linear fitting of experimental data. All experiments were repeated, 
independently, three times with at least 9 samples for each concentration.  
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Apoptosis measurements and Bromodeoxyuridine Incorporation Assay 
To quantify the apoptotic process, cancer cells were treated for 144 h with topotecan and 
pazopanib at a concentration corresponding to the experimental IC50 of cell proliferation, 
alone and in simultaneous combination or with their vehicles in hypoxic conditions. At the end 
of the experiment, cells were collected and the Cell Death Detection ELISA Plus kit (Roche 
Diagnostics, Laval, QC, Canada) was used. All the absorbance values were plotted as a 
percentage of apoptosis relative to control cells (vehicle only), which will be labeled as 100%. 
All experiments were repeated three times with at least three replicates per sample. For 
bromodeoxyuridine (BrdU) incorporation analysis, 24 h after seeding, LM2-4 cells were treated 
with the simultaneous combination of topotecan and pazopanib at their experimental IC50 and 
pulsed with BrdU for 18 h (BD Bioscience). Cells were fixed and stained using a FITC BrdU Flow 
Kit in accordance with the manufacturer's instructions (BD Biosciences). Populations in G0-G1, 
S, G2-M phase and apoptotic cells  were measured by flow cytometry with a FACScalibur (BD 
Biosciences). A total of 20,000 events were counted for each sample. Data were analyzed with 
FlowJo software (Tree Star). In each instance, flow cytometry was performed at least twice. 
 
Real-time PCR analysis of VEGF, HIF1α and ABCG2 gene expression on tumor and endothelial 
cells 
To evaluate the expression of the genes encoding human VEGF, HIF1α and ABCG2 proteins, 
6x104 HUVEC, 2x104 231/LM2-4 cells were grown in their respective media and treated with 
pazopanib, sunitinib, topotecan or concurrently in combination at a concentration 
corresponding to the experimental IC50 of cell proliferation or with vehicle alone, continuously 
for 144 h in hypoxic conditions. Total RNA was extracted from samples by using the RNEasy kit 
mini (Qiagen). Briefly, RNA (1 µg) was reverse transcribed using Omniscript RT Kit (Qiagen, 
Germantown, MD), according to the manufacturer's protocol. The resulting cDNA was diluted 
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(2:3) and then amplified by SYBR green-based real-time RT-PCR (QuantiTect® SYBR Green PCR 
Kit, QIAGEN) was performed using an ABI Prism 7000 Sequence Detection System (Applied 
Biosystems) with gene-specific primers purchased from Applied Biosystems. The polymerase 
chain reaction (PCR) thermal cycling conditions and optimization of primer concentrations 
were followed as per manufacturer’s instructions. Amplifications were normalised to HMBS 
(Hs_HMBS_1_SG, QuantiTect® Primer Assay Qiagen), and the quantitation of gene expression 
was performed using the ΔΔCt calculation, where Ct is the threshold cycle; the amount of 
target, normalised to the endogenous control and relative to the calibrator (vehicle-treated 
control cells), is given as 2-ΔΔCt. All experiments were repeated, independently, three times with 
at least 9 samples for each concentration. 
 
High Performance Liquid Chromatography (HPLC) analysis of topotecan concentrations in 
endothelial and cancer cells 
HUVEC, HMVEC-d, MDAMB231 and 231/LM2-4 cells (1 x 106) were incubated in RPMI 1640 
supplemented with 5 % FBS, in 10 cm2 dishes for 16 h at 37 ˚C. Topotecan stock solution in 
DMSO was diluted in pH 3 PBS (37 ˚C) to convert the compound into their active lactone. 
Topotecan [1 µM] was diluted in RPMI medium just before the start of the incubation. Cells 
were treated with topotecan [1 µM], pazopanib [1 µM], sunitinib [1 µM]  or their concurrent 
combinations at a ratio of [1:1]. After incubation for 5 min at 37 ˚C, the treatment medium was 
removed; cells were washed twice with cold PBS at pH 5 and scraped immediately. The cells 
were then ultrasonically lysed (10 s x 3). The lysate (200 µL) was added to 400 µL cold 
methanol and centrifuged (5 min, 7,500 g, 4 ˚C) for topotecan extraction to determine the 
intracellular drug concentration. Proteins in the remaining lysate were quantified by 
colorimetric assay (Bio-Rad Laboratories) [67]. The concentration of topotecan in the sample 
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was measured using a previously described sensitive high-performance liquid chromatography 
(HPLC) method [68]. 
 
Western Blot analysis 
231/LM2-4 breast cancer cells grown in RPMI 1640 supplemented with 5 % FBS  were treated 
with topotecan, pazopanib and sunitinib at a concentration corresponding to the experimental 
IC50 of cell proliferation or with their simultaneous combination in hypoxic conditions. At the 
end of the experiment, cells were lysed in protein lysis buffer (Cell Signaling Technology, 
Danvers, Mass) supplemented with 1 mM phenylmethanesulfonyl fluoride, 2 μg/mL aprotinin, 
and 1% phosphatase inhibitor cocktail, then stored at −80°C. Proteins (20 μg) were loaded 
equally onto 10% polyacrylamide gels, and electrophoresis was performed under denaturing 
conditions. Proteins were transferred onto polyvinylidene difluoride membranes, which were 
blocked in a 5% milk TBS-T solution for 1 hour then incubated overnight with each of the 
following primary antibodies: Anti-HIF1α antibody (diluted 1:500, Abcam), Anti-BCRP/ABCG2 
antibody [BXP-21] (1:1000, Abcam), and mouse monoclonal anti-human b-actin antibody 
(1:5000; Sigma-Aldrich). Membranes were incubated with either goat anti-mouse horseradish 
peroxidase (HRP) (1:5000, Sigma-Aldrich) for 30 minutes, followed by chemiluminescence 
detection solutions (ECL Plus; G.E. Healthcare, Baie d’Urfe, QC, Canada) and exposure to x-ray 
film (Kodak, Rochester, NY). Densitometric analysis was performed by ImageJ software 
(National Institutes of Health, Bethesda, Maryland); loading was normalized using bands for β-
actin.  
References are numbered as in the reference section of the manuscript  
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Supplementary table 1. IC50 values of topotecan, pazopanib and sunitinib on 231/LM2-4, HUVEC and 
HMVEC-d cells treated for 72h and 144 h. Results are expressed as mean ± S.D. Standard, standard in vitro 
treatments.  
LM2-4  Standard 72h  Metronomic 144h  
Topotecan  24±2.07 nM  3.01±0.58 nM  
Pazopanib  11±0.67 µM  2.18±0.53 µM  
Sunitinib  8±0.73 µM  2.635±0.33 µM  
HUVEC  
  
Topotecan  17.68±3.13 nM  1±0.13 nM  
Pazopanib  1.74±0.45 µM  1±0.22 µM  
Sunitinib  11±0.17 nM  3±0.95 nM  
HMVEC-d  
  
Topotecan  15.04±2.9 nM  1±1.26 nM  
Pazopanib  2.46±3.4 µM  0.45±0.047 µM  
Sunitinib  12.97±7.69 nM  4±3.78 nM  
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Supplementary figure 1. HIF1α gene expression in 231/LM2-4 cells exposed to topotecan (TPT) 24 
nM (standard in vitro treatment; Standard TPT), 3 nM (low dose metronomic; LDM) or with vehicle alone 
for 72 h or 144 h in hypoxic conditions. Columns and bars, mean values ± S.E., respectively.  
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Supplementary figure 2. Accumulation of topotecan in MDA-MB-231 (A), HUVEC (B) and HMVEC-d 
(C) cell lines after exposure to 1 µM topotecan (TPT) alone and in combination with pazopanib (PZ) or 
sunitinib (SU). Columns and bars indicate mean values ± S.D., respectively. *P<0.001 versus TPT. Small S.D. 
bars are not visible in the graph. 
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Supplementary figure 3. VEGF gene expression in 231/LM2-4 cells  exposed to topotecan (Topo) , 
pazopanib (pazo), sunitinib (SU) and their combinations or with vehicle alone for 144 h in hypoxic 
conditions. Columns and bars, mean values ± S.E., respectively. Small error bars are not visible in the graph. 
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Supplementary figure 4. Proapoptotic effects of topotecan (TPT) and pazopanib (PZ) on HUVEC 
endothelial cells treated for 144 h. Apoptosis measurements using the Cell Death Detection ELISA Plus kit 
(Roche Diagnostics). % Absorbance values are representative of HUVEC cytosolic nucleosomes. Columns 
and bars, mean values ±  S.E., respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
